Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
grade B 1.97 -2.96% -0.06
ATHX closed down 2.96 percent on Friday, May 17, 2019, on 1.87 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ATHX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish -2.96%
Pocket Pivot Bullish Swing Setup -2.96%
Stochastic Reached Overbought Strength -2.96%
Upper Bollinger Band Walk Strength -2.96%

Older signals for ATHX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Biotechnology Health Biopharmaceutical Life Sciences Pharmaceutical Industry Diseases Pharmaceuticals Diabetes Pharmacy Drug Discovery Clinical Trial Obesity Schizophrenia Inflammatory Bowel Disease Cardiovascular Disease Regenerative Medicine Design Of Experiments Pfizer Mesoblast Orthopedic Applications
Is ATHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.09
52 Week Low 1.35
Average Volume 738,329
200-Day Moving Average 1.7517
50-Day Moving Average 1.5612
20-Day Moving Average 1.653
10-Day Moving Average 1.732
Average True Range 0.1188
ADX 26.7
+DI 33.7263
-DI 12.7038
Chandelier Exit (Long, 3 ATRs ) 1.6736
Chandelier Exit (Short, 3 ATRs ) 1.7064
Upper Bollinger Band 1.9537
Lower Bollinger Band 1.3523
Percent B (%b) 1.03
BandWidth 36.382335
MACD Line 0.0986
MACD Signal Line 0.0533
MACD Histogram 0.0453
Fundamentals Value
Market Cap 224.4 Million
Num Shares 114 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -7.58
Price-to-Sales 61.05
Price-to-Book 8.00
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.20 2.11 2.16
Resistance 2 (R2) 2.11 2.05 2.11 2.15
Resistance 1 (R1) 2.04 2.01 2.00 2.05 2.14
Pivot Point 1.96 1.96 1.93 1.96 1.96
Support 1 (S1) 1.89 1.90 1.84 1.89 1.80
Support 2 (S2) 1.80 1.86 1.80 1.79
Support 3 (S3) 1.73 1.80 1.78
Support 4 (S4) 1.74